MX373977B - Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos. - Google Patents

Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos.

Info

Publication number
MX373977B
MX373977B MX2015015379A MX2015015379A MX373977B MX 373977 B MX373977 B MX 373977B MX 2015015379 A MX2015015379 A MX 2015015379A MX 2015015379 A MX2015015379 A MX 2015015379A MX 373977 B MX373977 B MX 373977B
Authority
MX
Mexico
Prior art keywords
alpha adrenergic
subject
treatment
tissue trauma
adrenergic agonists
Prior art date
Application number
MX2015015379A
Other languages
English (en)
Other versions
MX2015015379A (es
Inventor
Daniel W Gil
Edward C Hsia
Lydia L Andrews-Jones
Mingting Tian
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2015015379A publication Critical patent/MX2015015379A/es
Publication of MX373977B publication Critical patent/MX373977B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un método de tratamiento de traumatismo de tejido (como daño por radiación (como radiación solar y ultravioleta), heridas, moretones, quemaduras, ampollas, excoriación, incisiones, excisiones y úlceras) en un sujeto, que comprende administrar tópicamente al área del tejido del sujeto afectado por ese traumatismo una composición que comprende una cantidad terapéuticamente eficaz de al menos un agonista alfa adrenérgico (como clorhidrato de oximetazolina) La presente invención también proporciona un método para el alivio del dolor o incomodidad asociados con cirugía estética o plástica o tratamientos cosmetológicos a un sujeto que comprende administrar dicho agonista alfa adrenérgico.
MX2015015379A 2013-05-06 2014-05-05 Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos. MX373977B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819927P 2013-05-06 2013-05-06
PCT/US2014/036778 WO2014182610A2 (en) 2013-05-06 2014-05-05 Alpha adrenergic agonists for the treatment of tissue trauma

Publications (2)

Publication Number Publication Date
MX2015015379A MX2015015379A (es) 2016-03-04
MX373977B true MX373977B (es) 2020-07-13

Family

ID=50928274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015379A MX373977B (es) 2013-05-06 2014-05-05 Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos.

Country Status (13)

Country Link
US (2) US20140329874A1 (es)
EP (1) EP2994120B1 (es)
JP (1) JP2016518409A (es)
KR (1) KR20160005351A (es)
CN (1) CN105188691A (es)
AU (1) AU2014262960A1 (es)
BR (1) BR112015027984A2 (es)
CA (1) CA2911472A1 (es)
ES (1) ES2765264T3 (es)
MX (1) MX373977B (es)
RU (1) RU2015148910A (es)
SG (1) SG11201509173WA (es)
WO (1) WO2014182610A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016106377A (ru) * 2013-07-26 2017-08-31 Галдерма Ресерч Энд Девелопмент Способ лечения утолщения кожи
US11213480B1 (en) 2015-08-06 2022-01-04 Hikma Pharmaceuticals International Limited Phenylephrine hydrochloride ready-to-use solution
US10004734B2 (en) 2016-01-26 2018-06-26 Warren Scherer Compositions and methods for treating rebound erythema associated with topical alpha-adrenergic agonists
EP3530269A4 (en) * 2016-10-21 2020-05-27 Cellvertics Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DIABETES AND / OR HYPERLIPIDEMIA COMPRISING MIDORINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT
CN113197848B (zh) * 2021-05-24 2023-06-09 成都欣捷高新技术开发股份有限公司 一种重酒石酸间羟胺药物组合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1282855B (de) * 1966-08-27 1968-11-14 Merck Ag E Kosmetisches Lichtschutzmittel
US6009234A (en) * 1995-04-14 1999-12-28 Kabushiki Kaisha Toshiba Method of reproducing information
CA2154979A1 (en) * 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
PL1761266T3 (pl) * 2004-05-25 2013-09-30 Galderma Pharma Sa Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry
EP2055719A1 (en) * 2007-11-05 2009-05-06 Total Petrochemicals Research Feluy Optimisation of the ethylene polymerisation process
BRPI0819105A2 (pt) * 2007-11-08 2019-09-24 Aciex Therapeutics Inc composição para o tratamento e prevenção de edema de pálpebra
US20110224216A1 (en) * 2009-10-26 2011-09-15 Galderma Laboratories Inc. Methods of Treating or Preventing Acute Erythema
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
JP2013516482A (ja) * 2010-01-08 2013-05-13 レクロ・ファーマ，インコーポレーテッド 局所経皮用デクスメデトミジン組成物およびそれらの使用方法
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
AU2011336449B2 (en) * 2010-12-03 2016-07-07 Epi Health, Llc Pharmaceutical cream compositions comprising oxymetazoline
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
KR20140074883A (ko) * 2011-07-14 2014-06-18 알러간, 인코포레이티드 옥시메타졸린의 겔 조성물들 및 사용 방법
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном

Also Published As

Publication number Publication date
ES2765264T3 (es) 2020-06-08
EP2994120A2 (en) 2016-03-16
JP2016518409A (ja) 2016-06-23
KR20160005351A (ko) 2016-01-14
US20140329874A1 (en) 2014-11-06
HK1222558A1 (en) 2017-07-07
RU2015148910A (ru) 2017-06-13
SG11201509173WA (en) 2015-12-30
BR112015027984A2 (pt) 2017-09-05
WO2014182610A2 (en) 2014-11-13
AU2014262960A1 (en) 2015-11-26
WO2014182610A3 (en) 2014-12-31
EP2994120B1 (en) 2019-10-09
MX2015015379A (es) 2016-03-04
CA2911472A1 (en) 2014-11-13
US20200054608A1 (en) 2020-02-20
CN105188691A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
ZA202007149B (en) High elasticity hyaluronan compositions and methods of use thereof
CL2016000530A1 (es) Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).
MX384403B (es) Terapia de combinación para el tratamiento del cáncer.
MX2015010190A (es) Metodos de tratamiento topico para infecciones microbianas.
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
BR112013020159A2 (pt) método para inibir células tumorais de hamartoma
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX2013001227A (es) Compuestos y metodos para reparacion de piel.
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
WO2012149608A8 (en) Prenylated hydroxystilbenes
BR112016000350A8 (pt) métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX354123B (es) Composición antiséptica oral para tratamiento de mucositis oral.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX373977B (es) Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos.
EP3606570B8 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
MX376183B (es) Composiciones para el tratamiento de rosacea.
CO7240418A2 (es) Apósito con una liberación prolongada de agentes activos
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
WO2018094023A3 (en) Cyclic dipeptides and wound healing
MX377510B (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
UY33153A (es) Formulación tópica oftálmica de péptidos
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica

Legal Events

Date Code Title Description
FG Grant or registration